Venturelab
close

In CDR-Life we make transformative cancer immunotherapies

CDR-Life AG

Swiss Startup - CDR-Life Profile Main Image
Incorporated
01.02.2017
Headquarters
Horgen
Support

CDR-Life is a privately held, biotherapeutics company leveraging its unique antibody technology, M-gager®, to target highly cancer-specific intracellular proteins presented on the major histocompatibility complex (MHC). CDR-Life is advancing a robust pipeline of novel fully cancer-directed T cell engagers in various solid tumors. The team behind CDR-Life has extensive experience in all key areas of biologics development, hold numerous patents, and has previously invented new marketed medicines. CDR-Life has a strategic partnership with Boehringer Ingelheim to develop an antibody fragment-based therapeutic for geographic atrophy, a leading cause of blindness worldwide. For more information, please visit cdr-life.com and follow the Company on Twitter and LinkedIn.

News

05.02.2026

Startups make leadership changes amid growth (startupticker.ch)

16.09.2024

Positive clinical progress in the biotech scene (startupticker.ch)

01.05.2024

Triumphs and a setback in the biotech sector (startupticker.ch)

26.01.2024

New milestones for life sciences startups (startupticker.ch)

14.12.2023

CDR-Life advances into the clinical phase (startupticker.ch)

03.08.2023

CDR Life obtains milestone payment (startupticker.ch)

02.09.2022

Change of management in pursuit of growth (startupticker.ch)

13.04.2022

CDR-Life Closes $76 million Series A Funding (startupticker.ch)

11.05.2021

CDR-Life moves towards clinical trials (startupticker.ch)

14.09.2020

Strong Swiss delegation at Bio Europe (startupticker.ch)

Show all